TX-AVANCI
21.9.2022 15:10:10 CEST | Business Wire | Press release
Avanci announced that more than 100 million connected vehicles sold by more than 80 automotive brands are covered by an Avanci license, and that it predicts an additional 30-40 million connected vehicles to be licensed in the next year. Having licensed the majority of patented 2G, 3G, and 4G cellular technologies to the majority of the connected vehicle market, Avanci is the established industry solution for essential patent licensing in the automotive space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005093/en/
Avanci’s independent marketplace has transformed the way companies share technology. (Graphic: Avanci)
“We are incredibly pleased with the overwhelming adoption of our solution across both the telecommunications and automotive industries,” said Kasim Alfalahi, founder and chief executive officer of Avanci. “This level of participation validates our long-standing commitment to offer a simple, predictable and efficient solution for the Internet of Things, benefiting new technology adoption. We look forward to making licensing simpler and more efficient for a wide range of companies, as we explore new programs for massive, critical, and industrial IoT.”
“We are grateful to all the participants in our automotive licensing program for joining our effort to create a new way to license patents. Our work to date is a strong foundation for building our planned program for 5G connected vehicles,” added Laurie Fitzgerald, Senior Vice President at Avanci.
The auto makers participating in Avanci’s licensing program for 4G connected vehicles benefit from a license to all the 2G, 3G, and 4G cellular standard essential patents of the 51 patent owners participating as licensors in the program today, as well as patent owners that join as licensors in the future. Many of the new brands under license can be found at avanci.com/marketplace.
Avanci has transformed the way companies share technology by licensing intellectual property from dozens of different patent owners in a single transaction, at fixed rates, paid once for the lifetime of the product. By streamlining the technology sharing process, Avanci provides IoT companies with an efficient and transparent way to access the wireless technology needed for connected products.
About Avanci
Avanci believes that sharing patented technology in the Internet of Things era can be simpler. As an independent intermediary working at the intersection of different industries, our one-stop solution is designed to bring efficiency, convenience, and predictability to the licensing process. Since 2016, Avanci has been driving innovation forward by making connections through our marketplace. Companies with essential patents share their innovations with companies creating connected products for the IoT in one place, with one agreement, and for one fair, flat rate. In 2020, the World Economic Forum named Avanci a Technology Pioneer for its work in accelerating innovation for the Internet of Things.
Note to Editors
Please see further announcements from Avanci today about new licensees at avanci.com/about/#li-news.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005093/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder28.4.2026 14:42:00 CEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release
CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla
BMG and Concord Combine to Create World’s Leading Independent Music Company28.4.2026 14:11:00 CEST | Press release
Creates global platform to deliver superior service to artists, songwriters, and partnersUnlocks meaningful value through greater scale and strong cash flow, enabling continued investment in music rights, creative talent, and technologyBob Valentine to serve as CEO and Thomas Coesfeld as Chairman of the combined company, with global headquarters in Nashville and European Headquarters in BerlinCombined company to be named BMG with divisions “BMG Publishing” and “Concord Records” BMG and Concord today announced a definitive agreement to combine their businesses, creating the leading independent music company in the world. Operating under the BMG name, the combined company will bring together two highly complementary businesses to establish a scaled, global company delivering superior service to artists, songwriters, and partners – firmly grounded in an independent, artist-first model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study28.4.2026 14:00:00 CEST | Press release
NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race and Zero Occult Hypoxemia in Black or Hispanic Newborns Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly, there were no clinically meaningful skin pigmentation-related discrepancies and no occult hypoxemic events among Black or Hispanic patients, and in only one Caucasian patient overall. The Neonatal Pulse Oximetry Accuracy and Disparities by Skin Pigmentation (NeoPODS) study findings were presented from the podium at the Pediatric Academic Society in Boston, MA on Monday, April 27th at 10 am EST by lead author Dr. Heather Siefkes on behalf of colleagues at the University of California, Davis and the University of Mississippi
KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center28.4.2026 11:54:00 CEST | Press release
Delivering up to 130kW of liquid cooling per rack, the solution synchronizes cooling output with IT load in real time within seconds, to support high-density AI, large-scale computing, and HPC deployments, while reducing build time by 70% KAYTUS, a leading provider in AI infrastructure and liquid-cooling solutions, announced that its AI Compute Pod has received both the 2026 iF Design Award and Red Dot Award. This dual recognition not only stems from its outstanding performance in green, low-energy operation—achieving up to 130 kW cooling capacity per rack and a PUE as low as 1.1 through optimized thermal and power design—but also from its innovative approach to intelligent control and efficient O&M. The solution enables second-level synchronization between cooling and IT workloads, and leverages a dual-group control strategy to improve cooling energy efficiency by over 10%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom